

Taiwan unveils groundbreaking advancements in Al-driven drug discovery and cancer therapy

05 February 2025 | News



Allogeneic CAR-T achieves 90% tumour reduction

By partnering with Kyoto University in Japan, China Medical University (CMU) and Healthcare System in Taiwan has established a global research centre to spearhead advancements in cancer research, regenerative medicine, and AI-powered drug discovery.

The newly established CMU-Kyoto University Global Research Center strengthens ties in cancer research, translational medicine, and regenerative therapies. As part of this initiative, CMU Research Park integrates academic and industrial expertise to drive groundbreaking developments from laboratory research to clinical applications.

CMU and Healthcare System has recently revealed the world's first allogeneic CAR-T therapy for solid cancers, developed by Ever Supreme Bio Technology. This therapy has demonstrated a tumuor reduction rate of over 90% in pre-clinical studies. Human clinical trials are underway, with FDA approval marking a pivotal moment in solid tumour treatment.

CMU and Healthcare System's AI-driven initiatives include- Child Growth Assessment System; HiThings Tele-ICU (a state-ofthe-art system that integrates real-time patient data with 3D modeling for enhanced critical care management); Smart Health Scheduling where AI optimises health examination processes to streamline care delivery; Computer-assisted detection platform for Tc-99mTRODAT-1 (AI analyses brain images and visual scales to assist in diagnosing central nervous system motor disorders); and Long Term Care Record System and Medical Information Revise Assistant (MIRA) to enhance medical record accuracy and efficiency, allowing healthcare professionals to focus on patient care.